A Proposal for a Tool to Reduce the Frequency of HIV RNA Monitoring in People with HIV Treated with Long-Acting Antiretrovirals

European AIDS Clinical Society. Guidelines 2024. n.d. Available from: https://eacs.sanfordguide.com [Last accessed: December 21, 2024 ].

Waters L , Winston A , Reeves I , et al. BHIVA guidelines on antiretroviral treatment for adults living with HIV‐1 2022. HIV Med, 2022; 23(Suppl 5):3–115; doi: 10.1111/hiv.13446

Ripamonti D , Borghetti A , Zazzi M . Appropriateness of virological monitoring with long-acting injectable cabotegravir and rilpivirine. J Antimicrob Chemother, 2024; 79(10):2720–2724; doi: 10.1093/jac/dkae257

Moreno C , Izquierdo R , Alejos B , et al. CoRIS Cohort. Acceptability of long-acting injectable antiretroviral treatment for HIV management: Perspectives of patients and physicians in Spain. AIDS Patient Care STDS, 2024; 38(7):305–314; doi: 10.1089/apc.2024.0093

Hammer SM , Saag MS , Schechter M , et al. International AIDS Society-USA panel. Treatment for adult HIV infection2006 recommendations of the international AIDS Society–USA panel. JAMA, 2006; 296(7):827–843; doi: 10.1001/jama.296.7.827

Taramasso L , Bonora S , Cingolani A , et al. Question and answers on long-acting therapy with cabotegravir and rilpivirine in people with HIV. J Antimicrob Chemother, 2025; 80(3):610–623; doi: 10.1093/jac/dkaf025

Thornhill J , Garside L , Okoli C , et al. Similar virological outcomes and frequency of isolated viraemic events (Blips, Low-Level Viraemia and Suspected Virological Failure) between oral and long-acting antiretroviral therapy: A pooled analysis of phase III/IIIbcabotegravir + rilpivirine long-acting studies. J Int AIDS Soc, 2024; 27(S6):E26370. Abstract Supplement HIV Glasgow 10–13 November 2024 [Abstract P040], n.d.

Latham C , Urbaityte R , Sutton K , et al. HIV-1 RNA Blips and Low-Level Viral Replication: SOLAR (CAB+RPV LA vs BIC/FTC/TAF) [CROI Abstract 627]. In: 31st Conference on Retroviruses and Opportunistic Infections (CROI), 2024; pp. 3–6.

Armenia D , Spagnuolo V , Bellocchi MC , et al. PRESTIGIO Study Group. Use of next-generation sequencing on HIV-1 DNA to assess archived resistance in highly treatment-experienced people with multidrug-resistant HIV under virological control: Data from the PRESTIGIO Registry. J Antimicrob Chemother, 2024; 79(9):2354–2363; doi: 10.1093/jac/dkae236

Kityo C , Mambule IK , Musaazi J , et al. CARES trial team. Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial. Lancet Infect Dis, 2024; 24(10):1083–1092; doi: 10.1016/S1473-3099(24)00289-5

Fletcher L , Burrowes S , Sabin LL , et al. Long-acting injectable ART in practice: A mixed methods implementation study assessing the feasibility of using LAI ART in high risk populations and at alternative low barrier care sites. AIDS Patient Care STDS, 2024; 38(5):221–229; doi: 10.1089/apc.2024.0048

Thoueille P , Saldanha SA , Schaller F , et al. Swiss HIV Cohort Study. Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: A multicenter prospective observational study in Switzerland. Lancet Reg Health Eur, 2024; 36:100793; doi: 10.1016/j.lanepe.2023.100793

Gutiérrez F , Fernández-González M , Ledesma C , et al. Virological history predicts non-sustained viral suppression with long-acting cabotegravir and rilpivirine therapy, independent of pharmacokinetic parameters. Clin Infect Dis, 2024:ciae475; doi: 10.1093/cid/ciae475